Release Date: 31/05/21 18:27 Summary: Record FY21 results deliver positive EBITDA Price Sensitive: Yes Download Document 685.12KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%